Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
暂无分享,去创建一个
M. Konopleva | M. Andreeff | G. Garcia-Manero | T. Kadia | F. Ravandi | G. Borthakur | E. Jabbour | N. Daver | C. Dinardo | N. Short | S. Faderl | A. Ferrajoli | L. Masarová | Y. Alvarado | K. Sasaki | G. Montalban-Bravo | H. Kantarjian | Hind Al Azzawi | J. Senapati | Emmanuel Almanza